COMP <GO>
ANGO vs DCTH // ALTMAN Z-SCORE & DEBT/EQUITY
AngioDynamics Inc. (NASDAQ) VS. Delcath Systems Inc. (NASDAQ) • 15-METRIC TALLY: ANGO 1
— DCTH 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: DCTH
LAST: $12.35 (+1.81%) • MKT CAP: $519.4M
balance-sheet
2.12
LAST: $14.64 (-1.48%) • MKT CAP: $508.0M
balance-sheet
20.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANGO VS. DCTH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANGO | DCTH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 86.20% | -31.60 | DCTH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.40% | 0.80% | -24.20 | DCTH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.10% | 4.13% | -4.03 | DCTH | /fcf-yield <GO> |
| Operating Margin | -12.50% | 0.80% | -13.30 | DCTH | /operating-margins <GO> |
| Net Profit Margin | -11.50% | 3.20% | -14.70 | DCTH | /net-margins <GO> |
| Revenue Growth (YoY) | 9.50% | 129.10% | -119.60 | DCTH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.12 | 20.33 | -18.21 | DCTH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | DCTH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 46.0 | -1.50 | DCTH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $519.4M | $508.0M | $11.4M | ANGO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANGO REV | DCTH REV | ANGO GROSS % | DCTH GROSS % | ANGO FCF | DCTH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $320.2M | $85.2M | 54.6% | 86.2% | $508.0K | $21.0M |
| FY 2024 | $292.5M | $37.2M | 53.9% | 83.4% | -$14.6M | -$19.2M |
| FY 2023 | $303.9M | $2.1M | — | — | -$28.2M | -$31.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANGO // BETA —
DCTH // BETA —